Sophia Genetics price target raised to $7 from $6 at BTIG

BTIG analyst Mark Massaro raised the firm’s price target on Sophia Genetics (SOPH) to $7 from $6 and keeps a Buy rating on the shares. The company delivered a solid Q3 revenue beat and raise, and this small cap name looks well-positioned to make a big move in 2026, the analyst tells investors in a research note. Management also sees signs of a recovery building in biopharma, which when added to more clinical customers coming online at higher selling prices, will mark an inflection point in revenue and margin, the firm added.